NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Moderna, Inc. (MRNA) Stock Analysis

Moderna, Inc. (MRNA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MRNA

$245.81

+$3.73 (+1.54%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MRNA with… →

MRNA Key Statistics

As of Oct 21, 2026
Trading
Open
$242.20
Previous Close
$242.08
Day's Range
239.55–254.48
52-Week Range
22.28–254.48
Volume
15.94M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.10
Valuation
Market Cap
$98.14B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
44.05
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.98
Financials (FY)
Revenue (FY)
$1.92B−39.92%
Net Income (FY)
−$2.82B
Profit marginThe share of revenue left as profit after all costs and taxes.
−141.43%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
399.24M
1-Year Return
+794.18%
Dividend and dates
Earnings Date
November 6, 2026
Avg Volume
19.51M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MRNA closed at $245.81, +794.18% over 1 year.

Moderna, Inc. (MRNA) has a market capitalization of $98.14B.

In fiscal 2025, MRNA reported revenue of $1.92B.

MRNA Stock Return by Calendar Year

Moderna, Inc. (MRNA) return since Dec 2018: what $10,000 became

1 year
$10,000 $89,418
+794.18%
5 years
$10,000 $7,239
−27.61%
Since Dec 2018
$10,000 $132,156
+1,221.56%

If you had invested $10,000 in Moderna, Inc. (MRNA) at the close on December 7, 2018, the earliest close on record here, it would have been worth $132,156 at the close on October 21, 2026: +1,221.56% in total, +38.81% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+733.54%
2025−29.08%
2024−58.19%
2023−44.63%
2022−29.28%
2021+143.11%
2020+434.10%
2019+28.09%
2018 (partial year)−17.90%

As of October 21, 2026.

MRNA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.92B−$2.82B−146.8%
2024$3.20B−$3.56B−111.3%
2023$6.75B−$4.71B−69.8%
2022$18.88B$8.36B44.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.92B$1.05B−$3.07B−$2.82B−146.8%
2024$3.20B$1.74B−$3.95B−$3.56B−111.3%
2023$6.75B$2.06B−$4.24B−$4.71B−69.8%
2022$18.88B$13.46B$9.42B$8.36B44.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MRNA Valuation vs Biotechnology Median

Median of 608 stocks
MetricMRNABiotechnology medianvs median
P/S ratio44.0513.303.3x the median
Profit margin−141.43%−38.31%103.1 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Moderna, Inc. (MRNA) carries a market capitalisation of $98.14B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 4,700 employees.

The most recent close on file for MRNA is $245.81, dated October 21, 2026. That is +$3.73 (+1.54%) against the previous close. Over the past 52 weeks the price has ranged from $22.28 to $254.48. The latest close sits 1,003.28% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.92B. That is −39.92% against the prior fiscal year, when revenue was $3.20B. The same year closed with a net loss of $2.82B. Profit margin runs at −141.43%. That is 103.1 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −7.98.

Across the 4 fiscal years on file, revenue moves from $18.88B in 2022 to $1.92B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 44.05 times revenue. On price-to-sales that is 3.3 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.1. Daily returns over the trailing 7 years annualize to a volatility of 99.82%. Over the trailing twelve months the total return is +794.18%. Measured over 5 years, that is −6.26% a year compounded.

Growth & Income

No dividend is on file for MRNA.

So far in 2026 the total return is +733.54%. Across the complete calendar years on file, 2020 returned +434.10% and 2024 returned −58.19%. Of the 7 complete calendar years on file, 3 finished higher.

Peer Comparison

Moderna, Inc. (MRNA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Moderna, Inc. MRNA $98.14B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9
argenx SE ARGX $55.97B 33.9

The Biotechnology industry average P/E ratio is 16.6x. Moderna, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B

 RPRX

Royalty Pharma plc

$35.91B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Moderna, Inc.

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Visit website →